Your session is about to expire
← Back to Search
Peptide Receptor Radionuclide Therapy for Neuroblastoma
Study Summary
This trial is testing a new treatment for neuroblastoma, a cancer that typically affects young children. The goal is to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 711 Patients • NCT02175030Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can do most activities but may need help.I received a specific radioactive treatment within the last 8 weeks.My major organs are healthy enough to handle the treatment.My neuroblastoma is high-risk and hasn't fully responded to standard treatments.I am over 18 and can consent, or if under 18, my guardian can consent for me.I have undergone peptide receptor radionuclide therapy.My scan shows a lesion as active as or more than my liver.I am older than 12 months and eligible for treatments with higher radiation doses.I have not had radiation therapy to my kidneys in the last year.I have received somatostatin analogues recently.I am using or willing to use birth control or practice abstinence during the study.I have a history of heart failure with symptoms like shortness of breath or needing oxygen.You have a known sensitivity or allergy to somatostatin analogues.I will not start new cancer treatments within 2 weeks before receiving 64Cu-SARTATE.My kidney function is normal.I am not pregnant or breastfeeding.I am currently receiving hemodialysis.I have a stem cell product ready for use with enough cells.My liver tests, AST and ALT, are within normal limits.I have not had any other cancer in the last 3 years.I do not have any infections that are currently uncontrolled.
- Group 1: 67Cu-SARTATE
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there similar ongoing research projects to this one involving 67Cu-SARTATE?
"City of Hope Medical Center first studied 67Cu-SARTATE in 2015. Since then, there have been 19 completed clinical trials and presently 7 active studies. A high concentration of these ongoing trials are based out of Dallas, Texas."
In how many different geographical locations is this trial being run today?
"This trial has 9 enrolment sites, which are hospitals and medical centres located across the United States of America. The locations include University of Texas Southwestern Medical Centre in Dallas, Phoenix Children's Hospital in Phoenix, and Medical University of South carolina in Charleston."
How many people fit the qualifications for this experiment?
"In order to complete this study 34 patients that meet the inclusion criteria are required. The sponsor, Clarity Pharmaceuticals Ltd, will be conducting the trial at different locations including University of Texas Southwestern Medical Centre in Dallas, Texas and Phoenix Children's Hospital in Phoenix, Arizona."
To what conditions does 67Cu-SARTATE commonly lend therapeutic relief?
"67Cu-SARTATE is most commonly used as an intervention for trace element deficiency. It can also be prescribed to treat a variety of other conditions including obesity, IUD therapy, and IUD insertion."
Are new test subjects currently being accepted for this experiment?
"The trial is recruiting patients, as shown by the listing on clinicaltrials.gov. It was posted on 8/18/2020, with the latest update being 6/29/2022. The study seeks to enroll 34 participants at 9 sites."
Share this study with friends
Copy Link
Messenger